Researchers at Purdue Center for Cancer Research develop innovative, more cost-effective method to make drugs

March 12th 2019, Echt, Netherlands

As the Food and Drug Administration motivates the pharma industry to move away from traditional techniques for drug manufacture towards continuous processes, David H. Thompson, a Professor in Purdue’s Department of Chemistry & a member of the Purdue University Center for Cancer Research, has written a research paper on the continuous manufacturing of Lomustine. 


Lomustine is prescribed to people with Hodgkin lymphoma & certain brain cancers.  An important feature of the method developed is that it can be used for other pharmaceutical products. A video showing also the use of the Labtrix® S1 is available here.

The FDA put out a statement on Feb. 26 saying the continuous process allows manufacturers to more easily scale operations to meet demand and should help reduce drug shortages. The statement also said continuous manufacturing can provide a more robust, lower cost and diverse supply of drug products.


The goal is to improve manufacturing flexibility, enhance quality and uniformity, while lowering the costs for patients. Continuous manufacturing is an alternative to “batch” production where the drug product is produced continuously through a sequence of coupled flow reactors. Thompson and his team selected continuous manufacture for lomustine production because of improved quality monitoring throughout the manufacturing process. In addition, this approach can also reduce production costs by utilizing a safer and smaller production facility.


Do you want to learn more about this topic? Then use this link to view the complete article.


Do you want to know more about the Labtrix® S1 shown in the video and used in the research?

Then use this link to learn more about the Labtrix® S1.


We look forward to seeing more developments from Purdue!